IL321349A - צורות מינון של אנטגוניסטי הקולטן לאסטרוגן - Google Patents

צורות מינון של אנטגוניסטי הקולטן לאסטרוגן

Info

Publication number
IL321349A
IL321349A IL321349A IL32134925A IL321349A IL 321349 A IL321349 A IL 321349A IL 321349 A IL321349 A IL 321349A IL 32134925 A IL32134925 A IL 32134925A IL 321349 A IL321349 A IL 321349A
Authority
IL
Israel
Prior art keywords
unit dosage
dosage form
diluent
compound
weight
Prior art date
Application number
IL321349A
Other languages
English (en)
Inventor
Rampurna Prasad Gullapalli
David C Myles
Jing Jim Zhang
Stephanie Marie Noe Emory
Digvijay Babar
Yongqiang Li
Original Assignee
Olema Pharmaceuticals Inc
Rampurna Prasad Gullapalli
David C Myles
Jing Jim Zhang
Stephanie Marie Noe Emory
Digvijay Babar
Yongqiang Li
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olema Pharmaceuticals Inc, Rampurna Prasad Gullapalli, David C Myles, Jing Jim Zhang, Stephanie Marie Noe Emory, Digvijay Babar, Yongqiang Li filed Critical Olema Pharmaceuticals Inc
Publication of IL321349A publication Critical patent/IL321349A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL321349A 2022-12-09 2023-12-08 צורות מינון של אנטגוניסטי הקולטן לאסטרוגן IL321349A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263431515P 2022-12-09 2022-12-09
PCT/US2023/083202 WO2024124182A1 (en) 2022-12-09 2023-12-08 Dosage forms of an estrogen receptor antagonist

Publications (1)

Publication Number Publication Date
IL321349A true IL321349A (he) 2025-08-01

Family

ID=91380266

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321349A IL321349A (he) 2022-12-09 2023-12-08 צורות מינון של אנטגוניסטי הקולטן לאסטרוגן

Country Status (8)

Country Link
EP (1) EP4629971A1 (he)
JP (1) JP2026500166A (he)
KR (1) KR20250116048A (he)
CN (1) CN120322224A (he)
AU (1) AU2023390702A1 (he)
IL (1) IL321349A (he)
MX (1) MX2025006443A (he)
WO (1) WO2024124182A1 (he)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240142622A (ko) * 2015-10-01 2024-09-30 올레마 파마슈티컬스 인코포레이티드 테트라히드로-1H-피리도[3,4-b]인돌 항에스트로겐 약물
TWI843707B (zh) * 2017-09-26 2024-06-01 美商提薩羅有限公司 尼拉帕尼（ｎｉｒａｐａｒｉｂ）調配物

Also Published As

Publication number Publication date
MX2025006443A (es) 2025-07-01
EP4629971A1 (en) 2025-10-15
WO2024124182A1 (en) 2024-06-13
CN120322224A (zh) 2025-07-15
AU2023390702A1 (en) 2025-06-12
KR20250116048A (ko) 2025-07-31
JP2026500166A (ja) 2026-01-06

Similar Documents

Publication Publication Date Title
CN116478141B (zh) 氘代kras抑制剂药物及用途
CN108395452A (zh) 作为钠通道调节剂的吡啶酮酰胺的前药
TWI845657B (zh) (s)-1-(4-氟苯基)-1-(2-(4-(6-(1-甲基-1h-吡唑-4-基)吡咯并[2,1-f][1,2,4]三嗪-4-基)哌嗪基)-嘧啶-5-基)乙-1-胺之晶形及其製造方法
CN102510855B (zh) N-[3-氟-4-({6-(甲基氧基)-7-[(3-吗啉-4-基丙基)氧基]-喹啉-4-基}氧基)苯基]-n′-(4-氟苯基)环丙烷-1，1-二甲酰胺的晶形
EA036325B1 (ru) Фармацевтическая композиция на основе твердой дисперсии ингибитора idh1
CN102639536B (zh) 吡啶衍生物的无水晶型
MXPA03001725A (es) Heterociclos biciclicos, medicamentos que contienen estos compuestos, su uso y metodos para su produccion.
CN1202825A (zh) 蛋白激酶c抑制剂
CN105294717B (zh) 一种egfr抑制剂的盐、晶型及其用途
US20250049768A1 (en) Methods of treating estrogen receptor-associated diseases
TW202300492A (zh) 選擇性雌激素受體降解劑
IL321349A (he) צורות מינון של אנטגוניסטי הקולטן לאסטרוגן
CN117447385B (zh) 氘代的3-氨甲基-4-苯基哌啶-4-醇类化合物的制备及其用途
CN108419436B (zh) 一种取代的吡嗪甲酰胺类化合物及包含该化合物的组合物及其用途
CN114504574B (zh) 一种2-((2-甲氧基苯基)磺酰基)异吲哚啉类化合物药物制剂及其制备方法
CN120676939A (zh) Pi3k抑制剂及其制备和使用方法
TW200811144A (en) Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
CN113966330A (zh) PLK4抑制剂(1R,2S)-(E)-2-(3-(4-((顺式-2,6-二甲基吗啉)甲基)苯乙烯基)-1H-咪唑-6-基)-5’-甲氧基螺[环丙烷-l,3’-吲哚啉]-2’-酮富马酸盐的晶型S4
EP4631496A1 (en) Solid dispersion, preparation method therefor, and use thereof
RU2828311C1 (ru) Фармацевтическая композиция, способ ее получения и ее применение
TWI814468B (zh) 藥用組合物、其製備方法及用途
TW201125861A (en) CDC7 inhibitor salts
WO2023197934A1 (zh) 阿片受体拮抗剂缀合物的固体盐型、晶型及其制备方法、组合物和用途
CN118459465A (zh) 氘代稠合杂环化合物及其制备方法和药物组合物、结合物及应用
WO2023091550A1 (en) Methods of treating estrogen receptor-associated diseases